BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37976838)

  • 1. Super-enhancer-associated EEPD1 facilitates EMT-mediated metastasis by regulating the PI3K/AKT/mTOR pathway in gastric cancer.
    Jin Y; Xia Y; Du H; Xiang T; Lan B; Wei S; Li H; Huang H
    Biochem Biophys Res Commun; 2023 Dec; 689():149188. PubMed ID: 37976838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
    Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
    Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
    Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
    Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2E1 changes the biological function of gastric cancer cells via the PI3K/Akt/mTOR signaling pathway.
    Wang RY; Chen XW; Zhang WW; Jiang F; Liu MQ; Shen XB
    Mol Med Rep; 2020 Feb; 21(2):842-850. PubMed ID: 31974627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.
    Liu Y; Chen S; Xue R; Zhao J; Di M
    Biochem Biophys Res Commun; 2016 Feb; 470(2):350-355. PubMed ID: 26780727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
    Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
    Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Qian Y; Yan Y; Lu H; Zhou T; Lv M; Fang C; Hou J; Li W; Chen X; Sun H; Li Y; Wang Z; Zhao N; Gu Y; Ding Y; Liu Y
    Anticancer Agents Med Chem; 2019; 19(14):1754-1761. PubMed ID: 31364518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CLEC5A promotes the proliferation of gastric cancer cells by activating the PI3K/AKT/mTOR pathway.
    Wang Q; Shi M; Sun S; Zhou Q; Ding L; Jiang C; Bian T; Jia F; Liu Y; Qin J
    Biochem Biophys Res Commun; 2020 Apr; 524(3):656-662. PubMed ID: 32033754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.
    Xing X; Zhang L; Wen X; Wang X; Cheng X; Du H; Hu Y; Li L; Dong B; Li Z; Ji J
    Anticancer Drugs; 2014 Nov; 25(10):1129-40. PubMed ID: 25035961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ox-LDL-mediated ILF3 overexpression in gastric cancer progression by activating the PI3K/AKT/mTOR signaling pathway.
    Sun D; Zhang M; Wei M; Wang Z; Qiao W; Liu P; Zhong X; Liang Y; Chen Y; Huang Y; Yu W
    Aging (Albany NY); 2022 May; 14(9):3887-3909. PubMed ID: 35507914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Li YJ; Wang Y; Wang YY
    J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastasis suppressor protein 1 regulated by PTEN suppresses invasion, migration, and EMT of gastric carcinoma by inactivating PI3K/AKT signaling.
    Wang H; Zhao Y; Cao L; Zhang J; Wang Y; Xu M
    J Cell Biochem; 2019 Mar; 120(3):3447-3454. PubMed ID: 30246429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daidzin targets epithelial-to-mesenchymal transition process by attenuating manganese superoxide dismutase expression and PI3K/Akt/mTOR activation in tumor cells.
    Yang MH; Jung SH; Um JY; Kumar AP; Sethi G; Ahn KS
    Life Sci; 2022 Apr; 295():120395. PubMed ID: 35181309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
    Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
    Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
    Sun C; Tao Y; Gao Y; Xia Y; Liu Y; Wang G; Gu Y
    Biomed Pharmacother; 2018 Feb; 98():416-423. PubMed ID: 29278851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mir-20a-5p induced WTX deficiency promotes gastric cancer progressions through regulating PI3K/AKT signaling pathway.
    Li J; Ye D; Shen P; Liu X; Zhou P; Zhu G; Xu Y; Fu Y; Li X; Sun J; Xu J; Zhang Q
    J Exp Clin Cancer Res; 2020 Oct; 39(1):212. PubMed ID: 33032635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway.
    Song SZ; Lin S; Liu JN; Zhang MB; Du YT; Zhang DD; Xu WH; Wang HB
    J Cell Physiol; 2019 Aug; 234(10):18587-18601. PubMed ID: 30953349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of Long Noncoding RNA_GAS5 Suppresses Cell Proliferation and Metastasis in Laryngeal Cancer via Regulating PI3K/AKT/mTOR Signaling Pathway.
    Liu W; Zhan J; Zhong R; Li R; Sheng X; Xu M; Lu Z; Zhang S
    Technol Cancer Res Treat; 2021; 20():1533033821990074. PubMed ID: 33641529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.